SBIR TOPIC 431 - MOBILE ORAL-CANCER SCREENING AND TREATMENT (MOST) SYSTEM FOR LOW-RESOURCE SETTINGS
SBIR TOPIC 431 - MOBILE ORAL-CANCER SCREENING AND TREATMENT (MOST) SYSTEM FOR LOW-RESOURCE SETTINGS
批准号:
10706238
负责人:
RONGGUANG LIANG
金额:
$39.99万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-09-15 至 2023-09-14
关键词:
AddressDeveloped CountriesDiagnosisDisease ProgressionEarly DiagnosisFDA approvedImageLesionLightMalignant - descriptorMalignant NeoplasmsModalityMorbidity - disease rateMusOralOral StageOropharyngeal Squamous Cell CarcinomaPUVA PhotochemotherapyPatientsPerformancePhotochemistryResearchResource-limited settingScreening for Oral CancerSmall Business Innovation Research GrantStage at DiagnosisSurvival RateSystemTechnologyTimeUnited States National Institutes of HealthXenograft Modelbasecosthigh riskhigh risk populationlow and middle-income countriesmalignant mouth neoplasmmortalitypremalignantrural areasubcutaneoussuccess
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Oral and oropharyngeal squamous cell carcinoma (OSCC) together rank as the sixth most common cancer worldwide, it is the most common cancer in some low- and middle- income countries (LMICs). The poor survival rate in LMICs and rural regions in developed countries is mainly due to late diagnosis and the resultant progression of disease to an advanced stage at diagnosis. Motivated by the successes in the two different NIH UH2/UH3 projects for detecting and treating pre- and early oral cancers, Light Research Inc (LRI) proposes to develop and commercialize a new integrated mobile oral-cancer screening and treatment (MOST) system, optimized for low-resource settings (LRS). It combines dual-modal oral cancer screening technology and photochemistry-based, FDA approved photodynamic therapy (PDT) modality. We will first develop the MOST system (Aim 1) and then demonstrate the imaging and treatment performance of MOST system with murine subcutaneous xenograft model (Aim 2). This project is significant because early diagnosis of oral cancers and timely treatment can reduce disease progression, reduce morbidity and mortality, and cut costs. It addresses the major barrier to screen high-risk population and treat patients with high risk oral premalignant and malignant lesions (OPML) and early-stage oral cancer in LRS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金